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A B S T R A C T
It is well known that heart and kidney functions are interdependent; primary disor-
ders of one organ have been shown to affect the other organ (organ cross-talk). Over 
the last decade, growing interest and attention has been drawn to this interaction; the 
term cardiorenal syndrome (CRS) has been coined and 5 types of CRS have been 
recognized, whereby a vicious cycle is proposed of acute or chronic dysfunction of 
either the kidney or the heart which can trigger and aggravate dysfunction of the other 
organ. This interrelation in which one system negatively influences the other system 
calls for a closer examination of its pathophysiology, a more systematic approach for 
the diagnosis and treatment of this syndrome, and more intensive investigation for 
potential preventive measures. An overview of these complex interactions is herein 
attempted. 
I N T R O D U C T I O N
The prevalence of heart failure is estimated at 1–2% of the adult population in de-
veloped countries, rising to ≥10% among individuals ≥70 years of age.1 Kidney function 
is adversely affected in most patients with heart failure, especially if advanced, and is 
an important predictor of clinical outcome. It is reported that 25–30% of patients with 
decompensated heart failure develop worsening kidney function, a condition termed 
cardiorenal syndrome (CRS), which constitutes a real clinical challenge.2-4 It has become 
abundantly clear that renal dysfunction has been associated with poorer outcomes in 
patients with heart failure with higher in-hospital, post-discharge and long-term mortal-
ity and prolonged duration of hospitalization.5 Higher annual mortality rates (~40%) 
are reported in patients with any impairment of renal function, reaching at even higher 
levels (~50%) in those with moderate to severe renal dysfunction, as compared with 
the mortality rates (~25%) in patients without renal dysfunction.6 It should be noted 
that impaired renal function is independently associated with increased risk for death 
and hospitalization in heart failure patients both in those with preserved as well as in 
those with reduced left ventricular ejection fraction.7 
On the other hand, according with the US statistics, the prevalence of any stage of 
chronic kidney disease has been estimated at 13%.8 Hence, chronic kidney disease has 
emerged as an important and independent predictor of cardiovascular disease, includ-
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ing coronary artery disease, left ventricular hypertrophy, and 
heart failure. This has led to the recognition of a significant 
overlap and intricate pathophysiological interactions between 
cardiovascular and kidney disease. Indeed, cardiovascular 
disease may account for greater than 50% of all deaths in pa-
tients with chronic kidney disease, with mortality rates noted 
to be 10- to 20-fold higher than in an age-matched population 
devoid of kidney disease. 
P A T H O P H y S I O l O G y
In patients with heart failure who are developing worsening 
renal function, there are mutual intricate interactions between 
the two organs (organ cross talk), with dire consequences. 
Either the pathophysiological mechanisms underlying heart 
failure, plus various comorbidities, and/or the administered 
therapies affect renal circulation and function leading to the 
development of concomitant renal failure (Fig. 1). Depending 
on several etiological and chronological interactions, CRS was 
recently classified into several types, including acute or chronic 
types, cardiorenal or renocardiac types, and primary or sec-
ondary types, all detailed below. The mechanisms underlying 
the CRS are multifactorial, including structural damage from 
atherosclerosis, hemodynamic alterations, neurohormonal 
effects, and inflammatory components.9-13 
FIGURE 1. Mechanisms of Cardio-Renal Syndrome. AVP = arginine vasopressin; Dis. = disease; DM = diabetes mellitus; EPO= 
erythropoietin; GFR = glomerular filtration rate; HF = heart failure; HF-PEF = heart failure with preserved ejection fraction; HF-
REF = heart failure with reduced ejection fraction; NO = nitric oxide; RA = renal artery; RAAS = renin angiotensin aldosterone 
system; SNS = sympathetic nervous system; Syndr. = syndrome
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In the setting of CRS, these cardiac and renal interactions 
involve several major contributors, including the sympathetic 
nervous system (SNS), the renin-angiotensin-aldosterone 
system (RAAS), the arginine-vasopresin (AVP) system, en-
dothelial dysfunction with nitric oxide (NO) inhibition and 
endothelin production.9-13 Venous congestion and volume 
overload play a significant role in the pathogenesis of worsen-
ing renal function in heart failure, particularly when perfusion 
is also impaired.12,14 
Renal failure is usually ascribed to pre-renal, renal and 
post-renal causes. Traditionally, in patients with heart failure, 
the etiology of renal failure has been considered pre-renal. 
However, a post-hoc examination of the ESCAPE (Evalua-
tion Study of Congestive Heart Failure and Pulmonary Artery 
Catheterization Effectiveness) trial indicated that impaired 
baseline renal function, but not worsening renal function, 
was strongly associated with poor outcome in patients with 
decompensated heart failure.15 Thus, compromised flow during 
heart failure may not be solely responsible for the development 
of renal insufficiency or renal function deterioration in these 
patients. In other words, a prerenal etiology on the basis of 
low forward flow, overdiuresis, or excessive vasodilation is not 
the mere primary cause of worsening renal function. The trial 
indicated that that biventricular failure rather than isolated left 
ventricular failure may be a marker of more advanced cardiac 
disease and thus may contribute to the development of renal 
insufficiency in these patients. Other likely explanations for 
the increased incidence of renal dysfunction in patients with 
advanced heart failure include older age and the higher preva-
lence of comorbidities in these patients, such as hypertension 
and diabetes, which may be responsible for both native renal 
disease and heart failure. Furthermore, comorbidities, such 
as hypertension, disrupt the mechanism of renal blood flow 
autoregulation, rendering the kidney more susceptible to in-
jury during heart failure treatment. Importantly, baroreceptor 
dysfunction and neurohormonal activation, as already alluded 
to, lead to increased vasoconstriction of the pre-glomerular 
afferent arterioles, which further compromises renal blood 
flow and glomerular filtration rate (GFR). Thus, improving 
only the hemodynamics, without concomitantly influencing the 
neurohormonal milieu, apparently may not ameliorate renal 
function or long-term outcomes.15 
In addition, inflammation seems to play an important 
role in both acute and chronic cardiac and kidney disease; it 
is speculated that circulating mediators of inflammation may 
function in this organ cross-talk.12 Thus, it may be even possible 
to develop anti-inflammatory strategies that might decrease 
the morbidity and mortality associated with these conditions. 
However, the preliminary results of anti-TNF strategies in 
heart failure patients have been disappointing, which renders 
these approaches more complex than initially considered.12, 13 
Finally, regardless of etiology, the presence or development 
of renal dysfunction in patients with heart failure is deemed a 
grave comorbid condition which confers increased mortality, 
approaching 50% at 1 year.3,6 
In patients with heart failure with preserved ejection frac-
tion, the pathogenesis of the cardiorenal syndrome has been 
attributed to similar mechanisms. Among them, main role is 
ascribed to an elevated intra-abdominal and central venous 
pressure; activation of the renin-angiotensin system; sympa-
thetic overactivity; oxidative injury and endothelial dysfunc-
tion.16 Furthermore, infections and drugs (e.g. nonsteroidal 
inflammatory agents) have been considered as precipitating 
factors. Among patients with heart failure with preserved ejec-
tion fraction, CRS is more common in older female patients 
with hypertension and/or diabetes mellitus. In this setting, CRS 
may be underdiagnosed more often than in patients with low 
ejection fraction, whereas the therapeutic options may be even 
more challenging in an effort to reduce the filling pressure 
while maintaining adequate volume status. 
On the other hand, chronic kidney disease has been noted 
to accelerate the risk for and development of cardiovascu-
lar disease (renocardiac disease).8 The pathophysiological 
mechanisms implicated may comprise hyperhomocysteinemia, 
elevated lipoprotein (a), oxidative stress, endothelial dysfunc-
tion, chronic inflammation, vascular remodelling, changes 
in platelet aggregation, neurohormonal activation, volume 
overload, reduced parenchymal mass, and hormone deficiency 
(e.g., vitamin D and erythropoietin). Another important factor 
to consider is that patients with chronic kidney disease, under 
the perception of a less favorable response or concern for treat-
ment intolerance, risk or toxicity, have often been excluded 
from and thus deprived of risk-modifying interventions and/or 
cardioprotective therapies (such as revascularization, aspirin, 
beta-blockers, and angiotensin-converting inhibitors). Thus, 
as cardiac disease directly contributes to renal disease, renal 
disease clearly confers an increased risk of cardiac disease 
(heart-kidney crosstalk). 
T y P E S  O F  C A R D I O  R E N A l  S y N D R O M E 
( T A B L E  1 ) 1 7 - 2 6
Type 1 CRS relates to acute cardiorenal syndrome, observed 
in acute heart failure, including cardiogenic shock or decom-
pensated congestive heart failure, inducing a concomitant 
abrupt renal injury, defined as a 0.3–0.5 mg/dl rise in serum 
creatinine, or a 9–15 ml/min decrease in glomerular filtration 
rate (GFR).20,21 Type 2 CRS relates to chronic cardiorenal 
syndrome, defined as chronic heart failure leading to chronic 
renal disease, due to microvascular and macrovascular kidney 
injury complicated by hemodynamic compromise.22 Type 
3 CRS relates to acute renocardiac syndrome, when acutely 
compromised renal function, as seen in volume depletion, 
acute glomerulonephritis or bilateral renal artery stenosis, 
causes acute cardiac injury and deterioration, induced by 
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fluid overload, electrolyte and metabolic imbalance, and 
uremia, manifested by heart failure, arrhythmia or ischemia.23 
Type 4 CRS, chronic renocardiac syndrome, describes chronic 
renal disease contributing to continual compromised cardiac 
function, cardiac hypertrophy, and predisposition to adverse 
cardiovascular events with hemodynamic consequences, chronic 
inflammatory processes and progressive atherosclerosis. Indeed, 
chronic kidney disease, defined as a reduction of glomerular 
filtration rate (GFR) <60 mL/min/1.73 m2 and/or the presence 
of renal injury lasting for >3 months, is increasing in incidence 
and prevalence worldwide, and constitutes a significant risk 
for cardiovascular events independent of conventional risk 
factors. Even the very early marker of mild renal function dis-
turbance, manifesting as microalbuminuria, is associated with 
an increased incidence of cardiovascular disease. Higher than 
expected rates of coronary events, congestive heart failure, left 
ventricular hypertrophy, cardiac arrhythmias, and sudden death 
plague all stages of chronic kidney disease, increasing sharply 
as renal function declines. The pathophysiology of type 4 CRS 
is multifactorial, progressive, and bidirectional between kidney 
and renal dysfunction. 24 It appears that, in the absence of acute 
ischemia, chronic kidney disease can lead to adverse cardiac 
remodeling and fibrosis, diastolic dysfunction, left ventricular 
dilatation and finally heart failure with reduced ejection frac-
tion.25 Type 5 CRS relates to secondary CRS caused by drugs 
or systemic disorders affecting both cardiac and renal function, 
such as diabetes mellitus, hypertension, autoimmune diseases, 
sepsis, amyloidosis, disseminated intravascular coagulation.26 
These disorders may cause acute (e.g. drugs or sepsis) or chronic 
CRS (e.g. diabetes). Treatment of the basic underlying disease 
is the mainstay of therapy. 
D I A G N O S I S
I M A G I N G 2 7 
Although a chest X-ray is the initial imaging study that all 
patients with heart failure are submitted to, and all physicians 
are familiar with, and remains an invaluable tool to evaluate 
for pulmonary congestion and volume overload and assess 
the severity of heart failure, most or all of them proceed to 
have further imaging studies which give more detailed and 
targeted information regarding the heart and kidney anatomy 
and function.
Echocardiography. Echocardiography provides valuable 
information about cardiac anatomy and function. Assessment 
of both systolic and diastolic left ventricular function can thus 
be made with this cardinal imaging technique and patients can 
be categorized into those with heart failure with low ejection 
fraction and those with preserved ejection fraction. The simple 
transthoracic approach usually suffices for routine diagnostic 
assessment, unless there are technical limitations in finding a 
window for the ultrasound beam or specific situations exist, such 
as mitral valve disease and prosthetic valves, which necessitate 
the use of transesophageal echocardiography. 
Stress Echocardiography/ Single Photon Emission Com-
puted Tomography (SPECT) / Positron Emission Tomography 
(PET). Exercise or pharmacological stress echocardiography 
and thallium scintigraphy are tests which are used to identify 
the presence and extent of myocardial ischemia or viability. 
Positron emission tomography may offer some advantages 
in testing for ischemia and/or viability, but due to its cost has 
currently a limited use. 
Coronary Angiography. Coronary angiography is the 
ultimate test and remains the gold standard as an imaging 
technique for assessing coronary anatomy and for guiding 
the performance of percutaneous coronary angioplasty and 
stenting. Caution should be exercised and measures taken 
to avoid or minimize the consequences of contrast-induced 
nephropathy, particularly in patients with diabetes or renal 
insufficiency, by providing adequate hydration and limiting 
the dose of the contrast agent used. 
Ultrasonography. In addition to echocardiography, ultra-
sound techniques, including renal ultrasound, and ultrasonog-
raphy of the inferior vena cava and chest, can be extremely 
helpful in establishing a diagnosis and correctly classifying CRS. 
Transthoracic echocardiography allows evaluation of ventricular 
diastolic and systolic functions, investigates pulmonary conges-
tion and pericardial effusion, and describes volume overload. 
Renal ultrasound helps clinicians to distinguish between acute 
and chronic renal failure, and exclude urinary tract dilation or 
pathological bladder repletion, and provides crucial informa-
tion regarding kidney volume or echogenicity.28 
Computed Tomography (CT) / Renal Scanning. Computed 
tomography (CT) coronary angiography has been used for 
specific cases to evaluate coronary anatomy, but conventional 
coronary angiography still remains the gold standard for as-
sessing coronary anatomy and for guiding percutaneous coro-
nary interventions. CT urography has supplanted intravenous 
urograms for the diagnosis of renal stones and neoplasms. 
TABlE 1. Types of Cardiorenal Syndome.17-26
• Type 1: Acute Cardio-Renal Syndrome with acute worsening of 
cardiac function leading to renal dysfunction
• Type 2: Chronic Cardio-Renal Syndrome with chronic abnormali-
ties in cardiac function leading to renal dysfunction
• Type 3: Acute Reno-Cardiac Syndrome with an acute worsening 
of renal function causing cardiac dysfunction
• Type 4: Chronic Reno-Cardiac Syndrome with chronic abnor-
malities in renal function leading to cardiac disease
• Type 5: Secondary Cardio-Renal Syndromes with systemic condi-
tions causing simultaneous dysfunction of the heart and kidney 
(e.g. sepsis, systemic lupus erythematosus, amyloidosis, diabetes 
mellitus, hypertension).
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Contrast-enhanced CT can evaluate renal veins and arteries, 
renal parenchyma and the collecting system. Caution should 
be exercised to prevent contrast-induced nephropathy. Tech-
netium-based renal scanning for radionuclide imaging of the 
kidney can be employed for the differential diagnosis of acute 
and chronic renal failure and evaluation of the renal function. 
Magnetic Resonance Imaging (MRI). Cardiac magnetic 
resonance (CMR) is a non-invasive technique that provides 
information about cardiac anatomy and function, but this is 
already available from echocardiography, which is simpler and 
less expensive. Thus, this imaging technique is reserved for some 
other more specific assessments or when the echocardiogram 
is non-diagnostic. CMR is a better method to assess volumes, 
mass, and wall motion. CMR is particularly useful in identifying 
inflammatory and infiltrative diseases of the myocardium, such 
as myocarditis, sarcoidosis, amyloidosis, etc. and most valuable 
in patients with complex congenital heart disease. MRI is also 
useful for the study of the genitourinary tract, particularly in 
staging of malignancies. Magnetic resonance angiography can 
be used to assess renal arteries, but its use is limited due to the 
risk of nephrogenic systemic fibrosis. 
C A R D I A C  B I O M A R K E R S  ( T A B l E  2 )
Natriuretic Peptides. Brain-type natriuretic peptide (BNP) 
and N-terminal pro BNP (NT-proBNP) are secreted from the 
ventricular myocardium in response to increased wall stress 
and their levels have now an established role in the diagnosis 
of acute decompensated heart failure and represent inde-
pendent predictors of cardiovascular morbidity and mortality. 
Natriuretic peptides are elevated in patients with CRS in whom 
acute renal dusfunction occurs as a consequence of acute heart 
failure, whether new or decompensated. According with the 
most recent heart failure guidelines,1 in the acute setting, levels 
of BNP ≥100 pg/mL or NT-proBNP ≥300 pg/mL are consist-
ent with heart failure, while in the chronic setting the recom-
mended levels are ≥35 pg/mL and ≥125 pg/mL, respectively. 
Mid regional pro-atrial natriuretic peptide (MR-proANP) is an 
emerging biomarker with high diagnostic accuracy for heart 
failure in patients presenting with dyspnea.29,30 Thus, in the 
acute setting MR-proANP can be used for diagnosis of heart 
failure with a cut-off point of >120 pmol/L.1 
Cardiac Troponins. Cardiac troponins (I or T) have now 
supplanted creatine kinase as specific markers for ischemic 
myocardial injury. Now with the availability of high-sensitivity 
assays,31,32 the sensitivity of diagnosing small myocardial in-
farctions has increased, but at the cost of a lower specificity, 
since moderate elevations of cardiac troponins are common in 
chronic renal failure patients and a plethora of other conditions 
without significant myocardial damage. Furthermore, heart 
failure per se is known to be associated with elevated levels of 
cardiac troponins in the absence of acute myocardial ischemia 
or infarction. Thus, when the two conditions coincide, troponins 
TABlE 2. Biomarkers of Cardio-Renal Syndrome (see text for discussion)
CARDIAC
RENAl
OTHER
Functional
(GFR)
Glomerular  
Permeability
Tubulointerstitial 
Damage
Natriuretic Peptides Creatinine Albuminuria NAG C- reactive protein
 BNP BUN KIM-1 Procalcitonin
 NT-proBNP Cystatin C NGAL ADM / MR-proADM
 MR-proANP IL-18 Copeptin
Cardiac Troponins (I/T) FABPs ADMA
Cytokines Klotho (deficiency)
 TNF-α
 IL-1
 IL-6
Myeloperoxidase
ADM = adrenomedullin; ADMA = asymmetric dimethylarginine; BNP = brain natriuretic peptide; BUN = blood urea nitrogen; FABPs = 
fatty acid-binding proteins; IL = interleukin; KIM-1 = kidney injury molecule 1; MR-proADM = mid-regional-proADM; MR-proANP = mid 
regional pro-atrial natriuretic peptide; NAG = N-acetyl-beta-D-glucosaminidase; NGAL = neutrophil gelatinase-associated lipocalin; NT-proBNP 
= N-terminal pro BNP; TNF = tumor necrosis factor
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may certainly be elevated and therefore, the sensitivity and 
specificity of this biomarker is compromised in these patients. 
Cytokines. Pro-inflammatory cytokines, such as tumor-
necrosis factor alpha (TNF-α), interleukin (IL)-1 and IL-6, 
may be overproduced and released in myocardial injury or 
dysfunction; however, these markers also suffer from specificity 
and practical applicability. 
Myeloperoxidase. Myeloperoxidase (MPO) is an enzyme 
associated with the inflammatory process involved in rupture 
of atherosclerotic plaques.33 In addition to acute coronary 
syndromes, MPO levels have been shown to correlate with 
BNP values and independently predict heart failure mortality. 
Due to its association with a wide range of pathology including 
inflammation and oxidative stress, MPO has been proposed as 
a potential biomarker in both cardiovascular and renal disease, 
but further studies are needed for its value in CRS. 
R E N A l  B I O M A R K E R S  ( T A B l E  2 )
The filtration ability of the kidney, expressed as the glo-
merular filtration rate (GFR), has been classically estimated by 
serum creatinine and other formulas mainly based on creatinine. 
However, GFR does not cover the whole function of the kid-
ney, which also involves glomerular permeability and tubular 
function, and additionally includes vitamin D metabolism and 
erythropoietin production. Thus, several markers other than 
creatinine have been employed to estimate kidney function.5,33-36
Glomerular Filtration Rate (GFR)
Serum Creatinine / Creatinine Clearance. Creatinine, 
filtered through the glomerulus and thus excreted in the urine, 
comes from the breakdown of creatine phosphate of skeletal 
muscles, but is also secreted by the tubules and thus overes-
timates GFR. Muscle wasting in heart failure or obesity also 
interfere with creatinine production, filtration and secretion 
and thus pose problems in determining GFR. Several correc-
tion formulas have been proposed, which include age, gender, 
or weight, race, blood urea nitrogen (BUN) and albumin. The 
most common formulas include the Cockcroft-Gault equation, 
as an estimate of creatinine clearance, and the (simplified) 
Modification of Diet in Renal Disease (sMDRD/MDRD) 
formulas (estimated GFR) (Table 3). However, all these for-
mulas still overestimate GFR in the lower levels of true GFR 
and underestimate GFR in the higher levels of true GFR. 
Recently, to account for the poor performance of the MDRD 
equation in the (near) normal and higher ranges of GFR, a 
new equation, the CKD-EPI equation was developed. This 
formula resembles the MDRD but has creatinine-dependent 
gender differences and produces higher estimated GFR at 
lower creatinine levels; however, this equation has still to be 
validated in heart failure.34
Blood Urea Nitrogen (BUN). BUN is a varying and rela-
tively unreliable marker of renal function compared with 
creatinine and relevant formulas, but it holds a value as a 
marker for the effectiveness of dialysis, but also as a predic-
tor of morbidity and mortality in patients with heart failure.37 
Cystatin C. Cystatin C is freely filtered through the glo-
merulus and completely reabsorbed and degraded in the tubu-
lus. Its level in the circulation is therefore an ideal marker of 
GFR.34, 35 Cystatin C has been shown to be superior to serum 
creatinine as an estimate of GFR. However, in heart failure, 
no data exist on the reliability of cystatin C to accurately esti-
mate GFR. Nevertheless, cystatin C appears to have a strong 
impact on prognosis of the CRS and the potential to assess the 
effect of mild renal dysfunction on cardiovascular outcomes; 
particularly, it has been shown to predict cardiovascular events 
and disease progression of heart failure and renal insufficiency 
in elderly patients at risk.38
Glomerular Permeability
Albuminuria. In patients with diabetes, hypertension, and 
chronic renal dysfunction, microalbuminuria (30–300 mg/24h) 
and macroalbuminuria (>300 mg/24h) are commonly observed. 
Albuminuria has been proposed as an important therapeutic 
target in patients with chronic renal insufficiency. Furthermore, 
albuminuria may serve as marker of prognosis in patients with 
heart failure and as a predictor of heart failure in patients 
without myocardial dysfunction, even when GFR is normal.34
Tubulointerstitial Injury
N-acetyl-beta-D-glucosaminidase (NAG). NAG, a lysoso-
TABlE 3. Most Commonly Used Formulas for GFR 
Measurement
I. Cockcroft-Gault equation (estimated creatinine clearance rate)
Creatinine Clearance (ml/min) =  
(140 - Age) x Body mass (kg)
 x GF
Serum Creatinine (mg/dL) x 72
GF = gender correction factor; 0.85 in women, 1.00 in men
Normal values for Creatinine Clearance: 75-115 in women; 95-145 
in men
II. Modification of Diet in Renal Disease (MDRD) formula 
(estimated GFR)
For Creatinine in mg/dL, simplified “4-variable MDRD”: 
eGFR = 186 x Serum Creatinine-1.154 x Age-0.203 x [1.212 if Black] x 
[0.742 if Female]
The normal range of GFR, adjusted for body surface area, is similar 
in men and women, and is in the range of 100-130 ml/min/1.73m2. In 
children, GFR measured by inulin clearance remains close to about 
110 ml/min/1.73m2 down to about 2 years of age in both sexes, and then 
it progressively decreases. After age 40, GFR decreases progressively 
with age, by about 0.4 - 1.2 mL/min per year
(http://en.wikipedia.org/wiki/Renal_function).
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mal enzyme formed in the proximal tubule and appearing in 
the urine in response to tubular injury, is a sensitive marker of 
proximal tubular damage and the occurrence of acute kidney 
injury or worsening renal function.34 In congestive heart fail-
ure, urinary NAG levels are significantly elevated compared 
with controls and associated with poorer clinical outcome, 
independent of GFR. However, higher levels of NAG are 
also encountered in other conditions, such as urinary tract 
infections, which may limit their specificity. 
Kidney Injury Molecule 1 (KIM-1). KIM-1 is a trans-
membrane protein found in urine only after proximal tubular 
epithelial cell injury, and thus may predict those patients that 
are at increased risk for deteriorating renal function. Urinary 
KIM-1 levels decrease after anti-hypertensive therapy. How-
ever, clinical data on KIM-1 expression in chronic heart failure 
are limited and again this molecule also lacks specificity.34 
Neutrophil Gelatinase-Associated lipocalin (NGAl). 
NGAL is a protein of small molecular weight, normally de-
tectable in serum in low levels, being secreted in lung, kidney, 
trachea, stomach, and colon, but freely filtered through the 
glomerulus and completely reabsorbed in the tubules. Thus, 
plasma NGAL levels are less specific for renal disease, as 
increased secretion occurs in inflammation, sepsis, or cancer; 
however, urine levels are more specific, since the NGAL that 
appears in the urine is secreted only from the tubules (plasma 
NGAL is filtered and totally reabsorbed). In acute kidney 
injury, both plasma and urine NGAL rise significantly, with 
very high concentrations of NGAL expressed in urine, which 
mostly comes from production in the distal nephron (loop of 
Henley and collecting ducts), although high levels of NGAL 
have also been observed during proximal tubular injury. Thus, 
NGAL measurements are clinically useful as predictors of 
acute kidney injury or worsening renal function. Recently, 
higher plasma NGAL levels were found to predict the occur-
rence of worsening renal function in patients admitted with 
acute heart failure.35 However, in chronic heart failure, NGAL 
levels, albeit increased, did not predict outcome, in contrast 
to both NAG and KIM-1.34 
Interleukin 18 (Il-18). Among a plethora of cytokines, 
IL-18 is a proinflammatory cytokine, which is increased in 
response to acute kidney injury, particularly from an ischemic 
insult, detectable in urine, preceding the rise in creatinine, but 
with a slower rise compared to NGAL. However, IL-18 is also 
increased in inflammatory conditions, such as arthritis and 
sepsis which limits its specificity. No studies have evaluated 
the ability of IL-18 to predict acute kidney injury or worsening 
renal function in the setting of heart failure.34 
Fatty Acid-Binding Proteins (FABPs). FABPs are proteins 
that bind selectively to free fatty acids. There are numerous 
different tissue-specific FABPs. Of these, liver FABP (L-FABP 
or FABP-1) and heart FABP (H-FABP or FABP-3) have been 
localized in the proximal or distal tubules, respectively. They 
are associated with impaired renal function from ischemic 
injury, deemed sensitive and specific biomarkers of acute kid-
ney injury. FABP-1 may even outperform NGAL and KIM-1 
in acute kidney injury. Limited data are available in patients 
with heart failure.34 
Klotho. The Klotho protein is a single-pass transmembrane 
protein expressed mainly in the kidney, the parathyroid gland 
and the choroid plexus.39,40 Klotho has pleiotropic regulat-
ing functions with an emerging role in cardiorenal disease. 
It is expressed in areas involved with calcium regulation, 
predominantly, among other areas, in the renal distal convo-
luted tubules. Klotho downregulation appears to be an early 
biomarker for kidney dysfunction and mineral dysregulation. 
It may play a pathogenetic role in the progression of chronic 
kidney disease, which has been suggested as a state of klotho 
deficiency. Klotho is also responsible for vascular calcification, 
which is one of the principal complications of chronic renal 
dysfunction. Furthermore, low plasma klotho concentrations 
have been independently associated with a higher likelihood 
of having cardiovascular disease. It remains to be seen whether 
this novel biomarker could be of value in patients with CRS. 
O T H E R  M A R K E R S  ( T A B l E  2 )
C-Reactive Protein. High-sensitivity C-reactive protein 
(hs-CRP) is an important biomarker of inflammation, use-
ful for predicting short- and long-term outcome in patients 
with cardiovascular disease. Similarly, chronic kidney disease 
belongs to chronic inflammatory diseases, and CRP has been 
useful in predicting mortality. However, despite the suggestion 
that the risk is lowered in patients with cardiovascular disease 
and elevated CRP who received statin therapy, this has not 
been consistently corroborated in patients with chronic kidney 
disease,41 indicating the complexity of this inter-relationship. 
Furthermore, there is some suggestion that CRP may not be a 
mere marker of inflammation, but it may be directly affecting 
endothelial function.12 
Procalcitonin. Procalcitonin is a marker for coincidental 
infection in patients with heart or renal failure. Procalcitonin 
may be more sensitive than C-reactive protein (CRP) in se-
vere inflammatory processes, such as in cardiogenic shock. 35 
As patients with cardiac and/or renal disease are frequently 
complicated by infection and/or sepsis, this marker is useful 
to aid the diagnosis of concomitant infection with additional 
prognostic capability. It can also be combined with other mark-
ers, e.g. MR-proANP, to differentiate patients with acute heart 
failure and superimposed pneumonia.35 
Adrenomedullin (ADM) / MR-proADM. Adrenomedullin 
(ADM) is expressed in endothelial cells and is a strong prog-
nostic marker for cardiovascular disease. However, due to its 
short half-life, assays have been technically difficult. Recently, 
the midregional-proADM (MR-proADM) peptide has been 
discovered and used as a more stable product and important 
prognostic marker of cardiovascular events in patients with 
heart failure or myocardial infarction.35 
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Copeptin. Copeptin, the C-terminal part of the prohor-
mone of vasopressin, is secreted from the posterior pituitary 
in response to hypovolemia and parallels the secretion of 
antidiuretic hormone (arginine vasopressin-AVP), being also 
a more stable counterpart of AVP. Studies have indicated that 
copeptin is a strong prognostic biomarker in patients with 
heart failure. It also appears to be a marker for albuminuria 
and renal failure as well. Thus, copeptin, a surrogate marker 
for AVP, may be a potential predictor of CRS.35 
Asymmetric Dimethylarginine. The amino acid asymmetric 
dimethylarginine (ADMA) acts as a potent endogenous inhibi-
tor of the enzyme NO synthase, which can lead to endothelial 
dysfunction, deemed as the initiator of the atherosclerotic 
process. Furthermore, the enzyme that metabolizes ADMA 
is located, along with NO synthase, in glomerular endothelial 
and tubular epithelial cells. Thus, NO availability can be locally 
compromised in the kidney and result in progressive damage. 
Consequently, ADMA can serve as a marker of chronic kidney 
disease progression; however, plasma ADMA is increased in 
several conditions associated with endothelial dysfunction 
(atherosclerosis, diabetes, hypertension, heart failure) and this 
lack of specificity has limited its use as a reliable biomarker 
in CRS.33 
T H E R A P E U T I C  I M P l I C A T I O N S
Due to a paucity of data with regards to treatment of heart 
failure in the setting of renal dysfunction or vice-versa, patient 
management in this grim setting remains empirical. 
D I U R E T I C S 
Hypervolemia remains the main feature of CRS of vari-
ous types. Targeting volume status can be effected by dietary 
sodium restriction and fluid removal with use of diuretics, 
and/or the combination of these two therapeutic maneuvers; 
in severe heart failure, hyponatremia can urge for additional 
fluid restriction.14 However, the use of aggressive diuresis with 
a loop diuretic (furosemide), which is often needed in these 
patients to respond, is prone to be associated with worsening 
renal function, especially in the presence of ACE inhibitors. 
Maintaining an optimal balance between the benefits of decon-
gestion and the potential adverse effects of therapies remains 
a challenge. When faced with resistance to diuretic therapy, 
which is a common theme in this scenario, either employing 
higher doses or continuous intravenous infusion of furosemide 
and/or adding a thiazide diuretic (e.g. metolazone) to the loop 
agent may occasionally induce a good response. However, un-
der these circumstances, the use of renal replacement therapy 
emerges. Indeed, renal replacement therapy via extracorporeal 
techniques for fluid removal with use of ultrafiltration has been 
proposed as a last resort in patients with severe congestion 
along with poor cardiac output.
VA S O D I l A T O R S 
The use of venous and/or arterial vasodilators has been 
considered to improve hemodynamics but not renal function, 
and, if aggressive, it can worsen renal perfusion. Furthermore, 
this therapy may promote neurohormonal activation with its 
attendant consequences. Nevertheless, in the setting of acute 
heart failure with high systolic arterial blood pressure (>140 
mmHg), in addition or concomitantly with the use of loop 
diuretics, intravenous nitroglycerin or even nitroprusside 
can alleviate pulmonary congestion, decrease both preload 
and afterload and stabilize the patient. Caution should be 
exercised lest the patient becomes hypotensive in which case 
renal perfusion can be acutely compromised. 
P O S I T I V E  I N O T R O P I C  S U P P O R T
Intravenous use of dobutamine, dopamine, milrinone and 
levosimendan has been routinely advocated to improve cardiac 
and renal hemodynamics, and facilitate diuresis, but without 
confirmation of any benefit from randomized controlled 
studies. Nevertheless, inotropic agents are commonly used in 
hypotensive or low-output states.1 “Renal” or low-dose (2-3 
μg/kg/min) dopamine has been proposed to have a selective 
renal vasodilatory and natriuretic effect, but this still remains 
dubious. Periodic (e.g. every 3 months) 24-hour intravenous 
infusion of levosimendan has served well several patients in our 
practice with advanced heart failure symptoms and low cardiac 
output state; concomitant support with intravenous dopamine 
allows patients with low blood pressure to better tolerate the 
infusion of levosimendan. Future studies may further define 
levosimendan’s role in CRS patients. 
A N G I O T E N S I N  C O N V E R T I N G  E N z y M E 
I N H I B I T O R S  ( A C E I )  /  A N G I O T E N S I N  R E C E P T O R 
A N T A G O N I S T S  ( A R B S )
Although ACE inhibitors or ARBs constitute the corner-
stone of heart failure therapy,1 the use of these agents in the 
presence of renal failure is hindered by a potential further 
increase in creatinine and worsening renal function. Thus, there 
should be very close monitoring of renal function parameters 
when initiating or further increasing the doses of these agents 
in this setting. 
B E T A  B l O C K E R S
Beta blockers have an important role in treating chronic 
heart failure by negating the detrimental effects of the sympa-
thetic system,1 but their role in CRS is limited due to abnormal 
hemodynamics. They can be re-started when patients get 
stabilized, usually at low doses. 
S T A T I N S
Due to their pleiotropic effects, in addition to their hy-
polipidemic actions, statins have been proposed to exert 
beneficial, cholesterol-lowering-independent effects in pa-
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tients with CRS. Specifically, investigators have focused on 
statin-conferred improvement of endothelial function by an 
increase in NO availability and/or by their antioxidant effects, 
and amelioration of vascular inflammation.42 Furthermore, 
statins have been shown to reduce coronary atherosclerotic 
volume, may improve cardiac remodeling and systolic and di-
astolic function in patients with early-stage cardiac injury, and 
may reduce the incidence of atrial fibrillation via attenuation 
of atrial remodeling, all beneficial effects for early treatment 
of patients with cardiovascular disease. The beneficial effects 
of statins in reducing cardiovascular events may also be seen 
in chronic kidney disease, but mostly in patients with mild to 
moderate disease and not consistently in end-stage disease.41 
Since hyperlipidemia has also been shown to be a risk factor 
for renal disease, it is also possible that statins might slow the 
rate of renal injury progression. Among statins, a new agent, 
pitavastatin, has been suggested as having more cardiovascular 
and renoprotective effects compared to other statins, associated 
with stronger pleiotropic effects, particularly the reduction of 
oxidative stress.42 Further data are needed to confirm these 
initial results. 
V I T A M I N  D  R E C E P T O R  A G O N I S T S
Vitamin D deficiency has been shown to affect a number of 
organ systems, including the renal and cardiovascular systems. 
Renal insufficiency in CRS leads to reduced synthesis of calci-
triol (active vitamin D) and inadequate clearance of phosphate, 
thus creating serum mineral imbalance with hypocalcemia 
and hyperphosphatemia, which have been correlated with 
increased cardiovascular events. In response, the parathyroid 
gland increases parathormone (PTH) secretion, which can 
further lead to parathyroid gland hyperplasia and secondary 
hyperparathyroidism. Increased PTH will promote vascular 
calcification and bone remodeling. In addition, decreased 
vitamin D can stimulate the RAAS, with all its deleterious 
consequences, further aggravating a vicious cycle of system 
dysfunction in CRS. On the other hand, vitamin D supple-
mentation may attenuate these issues and improve survival. 
However, vitamin D also elevates serum levels of calcium 
and phosphorus, while elective vitamin D receptor agonists 
provide similar efficacy but a lower increase in calcium and 
phosphorus. Thus, selective activation of vitamin D receptors 
may confer cardiorenal protection, offering a novel approach 
to managing these high-risk patients, as suggested by some 
preliminary studies, 43,44 albeit refuted by others.45 
I R O N  A N D  E R y T H R O P O I E T I N  T H E R A P y
Iron deficiency is commonly encountered in both chronic 
kidney disease and in chronic heart failure, and has been 
deemed an independent risk factor for increased mortality. 
Studies of correction of the anemia with intravenous iron in 
both renal and heart failure have shown an improvement in 
the anemia and, in some cases, in renal and cardiac function, as 
well as in exercise capacity and quality of life. If future studies 
confirm these preliminary results, this will offer a new addition 
to the therapeutic armamentarium of the cardiorenal syndrome. 
46 Before these data regarding iron therapy became available, 
there preceded an initial enthusiasm about the potential benefit 
of anemia therapy with use of erythropoietin agents. However, 
this enthusiasm has been recently curtailed by the results of 
newer studies and meta-analyses indicating the potential harm, 
in addition to increased cost, of this therapeutic approach, 
mainly due to untoward effects of erythropoietin including 
hypertension, thrombosis and cardiovascular complications 
and possible increased cancer risk. 47 Furthermore, in a recent 
meta-analysis, the use of erythropoietins to treat anemia in 
patients with heart failure was associated with a neutral effect 
on both mortality and non-fatal heart failure events. 48 Finally, 
it should be noted that the optimal hemoglobin target remains 
elusive, since studies have indicated that higher hemoglobin 
concentration targets >13 mg/dl are of no benefit and may 
indeed be harmful.47 
M I N E R A l O C O R T I C O I D  R E C E P T O R  ( M R ) 
A N T A G O N I S T S
Spironolactone and eplerenone have been used in heart 
failure patients with beneficial effects,1 but their use is limited 
to patients with normal renal function and normokalemia, as 
they may cause hyperkalemia and worsening renal function, 
especially in the elderly. On the other hand, small pilot studies 
using spironolactone in patients with end-stage renal disease on 
hemodialysis have indicated that it may be safe, without higher 
hyperkalemia rates, for short-term therapy and if electrolytes 
are closely monitored.49 
U l T R A F I l T R A T I O N 
It is widely recognized that worsening renal function, con-
ferred by various processes, in patients with decompensated 
heart failure has a negative impact.50 Among these processes, 
main contributors comprise the venous congestion, elevated 
levels of natriuretic peptides, systemic vasoconstriction, and 
diuretic resistance. In order to overcome this latter situa-
tion, extracorporeal ultrafiltration has been heralded as a 
novel therapy to ameliorate heart failure,50-52 however, such a 
potential benefit has not been confirmed by clinical studies. 
Indeed, the recent results of the Cardiorenal Rescue Study 
in Acute Decompensated Heart Failure (CARRESS-HF)53 
refute the efficacy of ultrafiltration. Ultrafiltration resulted in 
similar weight loss or improved renal function compared with 
pharmacologic therapy and similar rate of death or rehospi-
talization for acute heart failure. 
5 B  A P P R O A C H
The 5B approach has been proposed by Ronco et al, and 
includes balance of fluids (as reflected by body weight), blood 
pressure, biomarkers, bioimpedance vector analysis, and blood 
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volume.54 To facilitate maintaining fluid balance, volume status 
assessed by clinical examination, central venous pressure and 
body weight, monitoring fluid intake and output, measuring 
(plasma and urine) osmolality, electrolytes and acid-base status, 
all assist in avoiding dehydration or overhydration. Although 
blood pressure is not an ideal measure of volume status, as 
there are many compensatory mechanisms maintaining the 
blood pressure despite volume changes, when affected, it is still 
a good indicator of a significant volume disturbance, especially 
when combined with orthostatic vital sign (blood pressure and 
heart rate) measurements. Testing for myocardial biomark-
ers, such as the BNP, provides assistance with the diagnosis, 
prognosis and course of heart failure and/or response to 
therapy, although some limitations may apply, particularly in 
presence of renal insufficiency and obesity, in which cases the 
BNP cut-off for heart failure may need to be doubled. Renal 
injury biomarkers, such as the NGAL, may also assist in early 
diagnosing renal damage and guiding therapy. Bioimpedance 
vector analysis (BIVA) is a bedside noninvasive method for 
volume assessment which can be performed within minutes, by 
placing a pair of electrodes on the dorsal surface of the wrist 
and ipsilateral ankle, and then applying a 50-kHz current to the 
body. The relative hydration is graphically depicted by BIVA 
as vector length, which, if short, indicates volume overload, 
whereas longer vectors represent volume depletion. Combining 
BIVA with BNP measurement has an additive diagnostic and 
prognostic value.54 Finally, monitoring volume status during 
renal replacement therapy by measuring relative blood volume 
changes with optical or ultrasound techniques can enhance 
the assessment of the patient’s status and guide fluid removal. 
C A R D I A C  R E S y N C H R O N I z A T I O N  T H E R A P y
Cardiac resynchronization therapy (CRT), effected via 
biventricular pacing, has now been established as an important 
therapy in patients with refractory advanced heart failure, low 
ejection fraction and left bundle branch block.1 Recently, the 
indications have expanded to include patients at earlier stage 
of heart failure. There are some preliminary results that this 
electrical therapy may also benefit patients with the cardiorenal 
syndrome, although there is a known initial risk of contrast-
induced nephropathy during the procedure.55 
M E C H A N I C A l  S U P P O R T 
Finally, when all therapies fail and patients progress to 
end-stage status, left ventricular assist devices have been used 
to manage these patients with the hope that they will serve 
either as a bridge to transplant or as an effective destination 
therapy, being cognizant of the exuberant cost and risks that 
this aggressive therapy entails.1 However, patients having 
both heart failure and kidney failure are poor candidates for 
mechanical support, due to increased surgical risk and grim 
overall prognosis. For patients in cardiogenic shock, tempo-
rarizing measures include ventilator and intra-aortic balloon 
pump support, until more definitive therapies, if applicable, 
can be employed (e.g. revascularization). 
Other Therapies
Vasopressin receptor antagonists (vaptans) have been used 
to promote aquaresis and increase serum sodium in hypona-
tremic patients but studies have not confirmed any long-term 
benefit.1 Since elevated plasma adenosine levels have been 
reported in patients with heart failure and implicated in the 
associated renal dysfunction and diuretic resistance, adenosine 
receptor antagonists have been proposed to ameliorate renal 
function and promote water and sodium excretion. However, 
preliminary data have not ascribed any benefit to the use of 
these agents.11 Intravenous use of a recombinant BNP agent, 
nesiritide,1 available in the US, but not in Europe, has been 
shown to be an effective vasodilator, which improves both 
natriuresis and diuresis, not suffering from tachyphylaxis as 
nitroglycerin is. However, early data questioned its efficacy 
and raised questions regarding its potential to aggravate renal 
function and increase acute mortality, concerns which have not 
been fully disproved as yet.
C O N C l U S I O N  A N D  F U T U R E 
P E R S P E C T I V E
Real challenges have been encountered in the understand-
ing of the pathophysiology, the early diagnosis (e.g. with use of 
new biomarkers and/or other tools), and effective management 
of the cardiorenal syndrome, which, when fully developed, 
confers a grave prognosis in patients with decompensated 
heart failure. Although CRS has spawned some controversy,56 
it is widely recognized that intricate interactions have been 
implicated in a cascade of events involving a complex process 
of poorly unraveled cross-talk between the two vital organs, 
the heart and the kidney (Fig. 1).8-14,18-26,57 We are in dire need 
of new therapeutic strategies to be developed and evaluated 
in future studies in these patients and of a multidisciplinary 
approach with close collaboration of the cardiologist, the 
nephrologist and the internist to prevent and/or effectively 
manage this difficult and puzzling clinical entity. 
Admittedly, there is currently no effective medical treat-
ment to directly improve renal function in patients with CRS, 
however, therapies aimed at improving cardiac function have 
been promising in producing an increase in GFR with con-
sequent improvement in clinical outcomes. Although several 
novel therapies have turned our hope into hype, some more 
recent data give credence to and offer hope for a more ef-
fective approach. For example, cardiac myosin activators (e.g. 
omecamtiv mecarbil), directly activating the enzymatic pathway 
within the cardiac myocyte leading to ventricular contraction, 
are new unique inotropic agents, which have been shown 
in pre-clinical and clinical studies to be effective and hold 
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promise as a safer and more effective therapeutic approach 
for the treatment of systolic heart failure.58 Urocortins are en-
dogenous peptides that belong to the corticotrophin-releasing 
hormone family, hormones that are secreted in response to 
stress, and have been shown in pre-clinical studies to have 
beneficial effects on the cardiovascular, hemodynamic, renal, 
and neurohormonal systems.59 Serelaxin, a recombinant form 
of human relaxin-2 (a peptide hormone that increases during 
pregnancy mediating the maternal physiological cardiovascular 
and renal adaptations) was recently shown to have potential 
protective effects against organ damage. In the RELAX-AHF 
(Relaxin in Acute Heart Failure) study, serelaxin, given early 
in patients with acute heart failure, had favorable effects on 
the short-term changes in biomarkers of cardiac (troponin, 
NT-proBNP), renal (creatinine, cystatin-C), and liver damage 
(transaminases) and was associated with improved 6-month 
mortality.60 Importantly, early recognition of heart failure 
decompensation, via application of novel methods of detec-
tion of pulmonary venous congestion with measurement of 
bioimpedance and remote monitoring of volume status, would 
lead to individualized diuretic or other decongestive regimen 
to prevent florid venous congestion and abort worsening of 
renal function.61 Finally, novel approaches are just emerging 
with renal artery denervation techniques for refractory hyperten-
sion and heart failure treatment, which may earn a place in the 
future management of this complex syndrome.62 
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